Eli Lilly (LLY) has signed a global research and licensing deal with South Korea-based Rznomics to develop RNA-editing therapies, Rznomics said in a statement Thursday.
The partnership will use Rznomics' proprietary ribozyme platform to target treatments for sensorineural hearing loss.
Rznomics will lead early-stage research, while Lilly will handle later-stage development and global commercialization.
The total deal value could exceed $1.3 billion if all options are exercised, along with future royalties on sales. The upfront payment was not disclosed, according to the company.
Shares of Eli Lilly were up nearly 2% in recent trading.
Price: 729.33, Change: +13.77, Percent Change: +1.92
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.